Literature DB >> 22736455

Effect of HMG-CoA reductase inhibitors on antimicrobial susceptibilities for gram-negative rods.

Aaron R Farmer1, Clinton K Murray, Katrin Mende, Kevin S Akers, Wendy C Zera, Miriam L Beckius, Heather C Yun.   

Abstract

Epidemiologic evidence suggests a beneficial effect of HMG-CoA reductase inhibitors (statins) in sepsis, and in-vitro data exist for antimicrobial activity of statins against some bacteria and fungi. We examined whether statin exposure at physiologic concentrations enhances activity of selected antimicrobials against Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Escherichia coli. Broth microdilution was performed with and without dose-ranging concentrations of lovastatin, fluvastatin, atorvastatin, pravastatin and simvastatin. No effects on antimicrobial activity were demonstrated.
© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22736455     DOI: 10.1002/jobm.201100614

Source DB:  PubMed          Journal:  J Basic Microbiol        ISSN: 0233-111X            Impact factor:   2.281


  5 in total

Review 1.  Is There Potential for Repurposing Statins as Novel Antimicrobials?

Authors:  Emma Hennessy; Claire Adams; F Jerry Reen; Fergal O'Gara
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

Review 2.  Drug repurposing for the treatment of staphylococcal infections.

Authors:  Shankar Thangamani; Haroon Mohammad; Waleed Younis; Mohamed N Seleem
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

3.  Statins: antimicrobial resistance breakers or makers?

Authors:  Humphrey H T Ko; Ricky R Lareu; Brett R Dix; Jeffery D Hughes
Journal:  PeerJ       Date:  2017-10-24       Impact factor: 2.984

4.  Atorvastatin does not display an antimicrobial activity on its own nor potentiates the activity of other antibiotics against Acinetobacter baumannii ATCC17978 or A. baumannii AB030.

Authors:  Vanessa Kornelsen; Mark Unger; Ayush Kumar
Journal:  Access Microbiol       Date:  2021-11-30

5.  Rosuvastatin as forthcoming antibiotic or as adjuvant additive agent: In vitro novel antibacterial study.

Authors:  Hayder M Al-Kuraishy; Ali I Al-Gareeb; Ali K Al-Buhadily
Journal:  J Lab Physicians       Date:  2018 Jul-Sep
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.